(Q37997825)

26 August 2017

title

Advances in hepatitis C virus vaccines, part two: advances in hepatitis C virus vaccine formulations and modalities (English)

1 reference

26 August 2017

1 reference

0 references

1 reference

Farzin Roohvand

1

1 reference

26 August 2017

Niloufar Kossari

series ordinal

2

1 reference

26 August 2017

language of work or name

English

0 references

publication date

29 March 2012

1 reference

Expert Opinion on Therapeutic Patents

26 August 2017

published in

1 reference

26 August 2017

volume

22

1 reference

26 August 2017

issue

4

1 reference

26 August 2017

page(s)

391-415

1 reference

Hepatitis C virus therapies

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Interferon in the treatment of chronic hepatitis C: a drug caught between past and future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Advances in hepatitis C virus vaccines, Part one: Advances in basic knowledge for hepatitis C virus vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Hepatitis C virus soluble E2 in combination with QuilA and CpG ODN induces neutralizing antibodies in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

A self-adjuvanting lipopeptide-based vaccine candidate for the treatment of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Immunogenicity and tolerability of intradermal administration of an HCV E1-based vaccine candidate in healthy volunteers and patients with resolved or ongoing chronic HCV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Prospects for a vaccine against the hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

The major Epstein-Barr virus (EBV) envelope glycoprotein gp340 when incorporated into Iscoms primes cytotoxic T-cell responses directed against EBV lymphoblastoid cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

21 January 2018

ISCOMs and ISCOMATRIX.

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Pinocytosis and phagocytosis: the effect of size of a particulate substrate on its mode of capture by rat peritoneal macrophages cultured in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX vaccine: a phase I study in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

HCV core protein immunization with Montanide/CpG elicits strong Th1/Th2 and long-lived CTL responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Induction of potent cellular immune response in mice by hepatitis C virus NS3 protein with double-stranded RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Induction of multispecific Th-1 type immune response against HCV in mice by protein immunization using CpG and Montanide ISA 720 as adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Priming with CpG-enriched plasmid and boosting with protein formulated with CpG oligodeoxynucleotides and Quil A induces strong cellular and humoral immune responses to hepatitis C virus NS3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Hepatitis C virus-like particles combined with novel adjuvant systems enhance virus-specific immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Direct gene transfer into mouse muscle in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Modulation of the immune response induced by gene electrotransfer of a hepatitis C virus DNA vaccine in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

DNA immunization of mice and macaques with plasmids encoding hepatitis C virus envelope E2 protein expressed intracellularly and on the cell surface.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Effect of immunological adjuvants: GM-CSF (granulocyte-monocyte colony stimulating factor) and IL-23 (interleukin-23) on immune responses generated against hepatitis C virus core DNA vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Immunization with a DNA vaccine candidate in chronic hepatitis C patients is safe, well tolerated and does not impair immune response induction after anti-hepatitis B vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

In vivo clearance of hepatitis C virus nonstructural 3/4A-expressing hepatocytes by DNA vaccine-primed cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

In vivo efficacy of virus-derived peptides and virus-specific cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Challenges in the development of effective peptide vaccines for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Universal peptide vaccines - optimal peptide vaccine design based on viral sequence conservation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

SYFPEITHI: database for MHC ligands and peptide motifs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Immunogenicity and safety of different injection routes and schedules of IC41, a Hepatitis C virus (HCV) peptide vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Phase I clinical study of a peptide vaccination for hepatitis C virus-infected patients with different human leukocyte antigen-class I-A alleles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Cross-genotype-reactivity of the immunodominant HCV CD8 T-cell epitope NS3-1073.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Polytope DNA vaccine development against hepatitis C virus: a streamlined approach from in silico design to in vitro and primary in vivo analyses in BALB/c mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Construction of HCV-polytope vaccine candidates harbouring immune-enhancer sequences and primary evaluation of their immunogenicity in BALB/c mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Protective efficacy of serially up-ranked subdominant CD8+ T cell epitopes against virus challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Cross-talk between programmed death-1 and suppressor of cytokine signaling-1 in inhibition of IL-12 production by monocytes/macrophages in hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Fusion of HBsAg and prime/boosting augment Th1 and CTL responses to HCV polytope DNA vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

A vector-based minigene vaccine approach results in strong induction of T-cell responses specific of hepatitis C virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Neutralizing antibodies against 33 human adenoviruses in normal children in Rome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Efficient immunization of rhesus macaques with an HCV candidate vaccine by heterologous priming-boosting with novel adenoviral vectors based on different serotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Induction of primary human T cell responses against hepatitis C virus-derived antigens NS3 or core by autologous dendritic cells expressing hepatitis C virus antigens: potential for vaccine and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Nonreplicating vaccinia vector efficiently expresses recombinant genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Comparative immunogenicity analysis of modified vaccinia Ankara vectors expressing native or modified forms of hepatitis C virus E1 and E2 glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

An accelerated vaccine schedule with a poly-antigenic hepatitis C virus MVA-based candidate vaccine induces potent, long lasting and in vivo cross-reactive T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Induction of broad CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

T-cell vaccines that elicit effective immune responses against HCV in chimpanzees may create greater immune pressure for viral mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Recent advances in mucosal delivery of vaccines: role of mucoadhesive/biodegradable polymeric carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Oral immunization with HCV-NS3-transformed Salmonella: induction of HCV-specific CTL in a transgenic mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Oral immunization with attenuated Salmonella carrying a co-expression plasmid encoding the core and E2 proteins of hepatitis C virus capable of inducing cellular immune responses and neutralizing antibodies in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Transgenic crops for the production of recombinant vaccines and anti-microbial antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Development of a plant-derived subunit vaccine candidate against hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

In vitro stability of Cucumber mosaic virus nanoparticles carrying a Hepatitis C virus-derived epitope under simulated gastrointestinal conditions and in vivo efficacy of an edible vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Chimeric hepatitis B and C viruses envelope proteins can form subviral particles: implications for the design of new vaccine strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Localization and reactivity of an immunodominant domain in the NS3 region of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Recombinant virus-like particles as a carrier of B- and T-cell epitopes of hepatitis C virus (HCV).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

New views on immunopotentiators in modern vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.673589

10.1517/13543776.2012.673589

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference